Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Account Payables data on file, last reported at $3.9 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $3.9 million, up 246.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (up 45.24% YoY), and the FY2025 annual result was -$7.5 million, down 623.31% from the prior year.
• Change in Account Payables improved to $3.9 million in Q1 2026 per DNLI's latest filing, from -$3.4 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.8 million in Q2 2023 and troughed at -$4.4 million in Q3 2024.
• A 5-year average of $146882.4 and a median of $839000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables slumped 2098.72% in 2022, then soared 469.01% in 2023.
• A 5-year view of Change in Account Payables shows it stood at -$1.7 million in 2022, then retreated by 21.34% to -$2.1 million in 2023, then soared by 161.8% to $1.3 million in 2024, then slumped by 365.01% to -$3.4 million in 2025, then soared by 213.7% to $3.9 million in 2026.
• Business Quant data shows DNLI's Change in Account Payables at $3.9 million in Q1 2026, -$3.4 million in Q4 2025, and -$4.1 million in Q3 2025.